Dymon Asia Capital Singapore PTE. LTD. Purchases Shares of 4,200 Vertex Pharmaceuticals Incorporated $VRTX

Dymon Asia Capital Singapore PTE. LTD. purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 4,200 shares of the pharmaceutical company’s stock, valued at approximately $1,904,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Vertex Pharmaceuticals by 1.0% during the third quarter. Vanguard Group Inc. now owns 24,216,865 shares of the pharmaceutical company’s stock valued at $9,484,293,000 after acquiring an additional 243,088 shares during the last quarter. Capital Research Global Investors boosted its stake in shares of Vertex Pharmaceuticals by 4.6% during the fourth quarter. Capital Research Global Investors now owns 17,316,344 shares of the pharmaceutical company’s stock valued at $7,850,544,000 after acquiring an additional 763,063 shares during the last quarter. State Street Corp boosted its stake in shares of Vertex Pharmaceuticals by 0.7% during the fourth quarter. State Street Corp now owns 11,689,539 shares of the pharmaceutical company’s stock valued at $5,299,569,000 after acquiring an additional 83,539 shares during the last quarter. Capital International Investors boosted its stake in shares of Vertex Pharmaceuticals by 0.9% during the fourth quarter. Capital International Investors now owns 4,733,596 shares of the pharmaceutical company’s stock valued at $2,146,041,000 after acquiring an additional 44,537 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of Vertex Pharmaceuticals by 3.3% during the third quarter. Alliancebernstein L.P. now owns 4,522,586 shares of the pharmaceutical company’s stock valued at $1,771,226,000 after acquiring an additional 144,266 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on VRTX shares. Royal Bank Of Canada increased their price objective on Vertex Pharmaceuticals from $541.00 to $543.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Maxim Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 price objective on the stock in a research note on Wednesday, March 18th. Wall Street Zen lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 30th. Sanford C. Bernstein decreased their price objective on Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Finally, Morgan Stanley increased their price objective on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an “overweight” rating in a research note on Tuesday, May 5th. Twenty-two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $555.91.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Joy Liu sold 1,104 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $425.02, for a total value of $469,222.08. Following the sale, the executive vice president directly owned 20,729 shares of the company’s stock, valued at approximately $8,810,239.58. This trade represents a 5.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 318 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $423.73, for a total value of $134,746.14. Following the completion of the sale, the director directly owned 4,924 shares in the company, valued at approximately $2,086,446.52. The trade was a 6.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 11,133 shares of company stock valued at $4,973,106. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.0%

Shares of NASDAQ:VRTX opened at $444.92 on Friday. The stock’s 50-day moving average price is $437.14 and its two-hundred day moving average price is $452.33. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $507.92. The firm has a market cap of $112.92 billion, a price-to-earnings ratio of 26.39, a PEG ratio of 1.90 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The firm had revenue of $2.99 billion for the quarter, compared to analyst estimates of $2.99 billion. During the same period last year, the company earned $4.06 EPS. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 17.02 earnings per share for the current fiscal year.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex received bullish attention from market commentary highlighting that Wall Street remains interested in the stock despite a bearish “death cross” technical setup, suggesting investors are focusing more on the company’s fundamentals than the chart pattern. Article Title
• Positive Sentiment: The company announced new CASGEVY data at the European Hematology Association Congress, including the first European presentation of results in children ages 5–11 and additional global regulatory submissions, which could support longer-term growth for the gene-editing therapy. Article Title
• Positive Sentiment: Analysts and media coverage have been broadly upbeat on Vertex, including pieces describing it as a favored healthcare stock and a stock some investors view as attractive to buy now, reinforcing confidence in the name. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Vertex to $19.24 from $19.36, a small revision that may not materially change the long-term outlook but is a minor headwind for sentiment. Article Title
• Negative Sentiment: The stock has also experienced a recent pullback in some sessions, reflecting normal volatility and some profit-taking even as the broader narrative remains constructive. Article Title

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.